Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy.
Where this comes from
- Record sourced from PubMed, PMID 37321628.
- Also identified by DOI 10.1136/bmj-2022-069963 and PMC identifier 10266439.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>Yingyao Chen and colleagues</b> examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit
Medical subject headings
- Insurance
- Neoplasms